<DOC>
	<DOC>NCT01225341</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy and safety of Botulinum Toxin Type A as a preventative measure for Herpes Labialis.</brief_summary>
	<brief_title>Botulinum Toxin A for Herpes Labialis</brief_title>
	<detailed_description />
	<mesh_term>Herpes Labialis</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Males or females between the ages of 18 and 64. Have herpes simplex virus 1 (HSV1) with between 26 herpes labialis recurrences per year. Willingness and ability to comply with protocol requirements, including returning for followup visits and abstaining from exclusionary procedures for the duration of the study. Subjects of childbearing potential must have a negative urine pregnancy test result at Visit 1 and be willing able to use an acceptable method of birth control (e.g., barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study. Women will not be considered of childbearing potential if one of the following is documented on the medical history: postmenopausal for at least 12 months prior to study drug administration without a uterus and/or both ovaries has had a bilateral tubal ligation for at least 6 months prior to study drug administration. absence of an other physical condition according to the PI's discretion Willingness and ability to provide written photo consent and adherence to photography procedures (i.e., removal of jewelry and makeup). Willingness and ability to provide written informed consent prior to performance of any study related procedure. Subjects who are pregnant, nursing, planning to become pregnant, and/or not using a reliable form of birth control. Subjects with a known allergy or sensitivity to any component of the study medications or anesthesia. Active recurrence of herpes labialis. Botulinum toxin to the lower 1/3 of the face with the past 6 months. Significant concurrent illness such as diabetes, epilepsy, lupus, or congestive heart failure. Concurrent skin condition affecting area to be treated. Prior surgery on the area to be treated within 3 months of initial treatment or during the study. History or evidence of keloids or hypertrophic scarring. Current use of antivirals for the treatment of herpes labialis within 2 weeks prior to initiation of treatment (e.g., acyclovir, valaciclovir, famciclovir, and penciclovir). Topical use of overthecounter medications for the treatment or prevention of HSV1 (e.g., Abreva). Subjects currently using aminoglycoside antibiotics, curarelike agents or other agents that might interfere with neuromuscular function. Subjects with a diagnosis of Myasthenia Gravis, EatonLambert Syndrome, Amyotrophic Lateral Sclerosis, or any other disease that might interfere with neuromuscular function or current facial palsy. Current history of chronic drug or alcohol abuse. Concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study medication. Subjects who, in the Investigator's opinion, have a history of poor cooperation, noncompliance with medical treatment or unreliability. Enrollment in any active study involving the use of investigational devices or drugs.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>HSV-1</keyword>
	<keyword>Herpes labialis</keyword>
	<keyword>Cold sores</keyword>
	<keyword>Fever blisters</keyword>
</DOC>